Solid Biosciences Inc. Stock News

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional preclinical study of its low-dose oral interferon formulation against Omicron.

- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo -

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.76% and 77.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

- Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 -

Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding

Solid Biosciences Inc. (NASDAQ:SLDB ) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ET Company Participants Caitlin Lowie - VP, Communications and IR Ilan Ganot - Co-Founder, President and CE

Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading. Piper Sandler cut the price target for PayPal

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock

- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process -

Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.

The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the dela

Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.